Sector News

Merck KGaA appoints pharma head Oschmann as deputy CEO

September 18, 2014
Life sciences
(Reuters) – German drugs and chemicals maker Merck KGaA appointed the head of its pharma business, Stefan Oschmann, as deputy chief executive, it said on Thursday.
 
Oschmann, 57, will share strategic management functions and representation of the company with CEO Karl-Ludwig Kley as of Jan. 1, 2015, it said.
 
The promotion puts Oschmann in the frame to possibly succeed Kley, whose contract runs until September 2016.
 
Belen Garijo, 54, will take over leadership of the entire pharma business, according to the statement. Garijo is already CEO of Merck’s biopharmaceutical division, Merck Serono, to which she will add consumer health, allergy treatments and biosimilars.
 
(Reporting by Georgina Prodhan; Editing by Ludwig Burger)

comments closed

Related News

October 23, 2021

Novo Nordisk teams with CVS Health on obesity support program ahead of Wegovy DTC launch

Life sciences

As Novo Nordisk gears up to disrupt the obesity market with its newly approved weight-loss drug Wegovy, it is teaming with retail pharmacy giant CVS Health on a new education and nutrition coaching program for people taking anti-obesity meds.

October 23, 2021

GSK-backed Atreca inks license with Gates Medical Research Institute for malaria monoclonal antibody

Life sciences

The terms of the deal were undisclosed, but Atreca received $6 million from the Gates Foundation in 2012 to discover potential treatments for malaria, tuberculosis and HIV. The foundation has also given grant money to other biopharmas exploring malaria treatments, including Exscientia, which secured $4.2 million last year for such work.

October 23, 2021

A record number of biotechs are going public. Here’s how they’re performing.

Life sciences

At the start of the last decade, the IPO markets weren’t receptive to biotech companies. But by 2013, public investment was pouring into the industry, drawn by scientific advances and boosted by the newfound interest of a broader range of investors. Ever since, biotechs and their backers have ridden a multi-year boom. Keep track of them as they happen with this database.

Send this to a friend